MA26435A1 - Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant. - Google Patents
Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant.Info
- Publication number
- MA26435A1 MA26435A1 MA24730A MA24730A MA26435A1 MA 26435 A1 MA26435 A1 MA 26435A1 MA 24730 A MA24730 A MA 24730A MA 24730 A MA24730 A MA 24730A MA 26435 A1 MA26435 A1 MA 26435A1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- amido
- medicaments
- pharmaceutical compositions
- treatment method
- Prior art date
Links
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical class NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2229896P | 1996-07-23 | 1996-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26435A1 true MA26435A1 (fr) | 2004-12-20 |
Family
ID=21808875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA24730A MA26435A1 (fr) | 1996-07-23 | 1997-07-22 | Derives de benzylamine amido-substitues, leurs derives precurseurs de medicaments, leur procede de preparation, compositions pharmaceutiques les contenant et methode de traitement les utilisant. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6133265A (fr) |
| EP (1) | EP0918761B1 (fr) |
| JP (1) | JP2000515527A (fr) |
| AR (1) | AR008071A1 (fr) |
| AT (1) | ATE239002T1 (fr) |
| AU (1) | AU3671897A (fr) |
| CA (1) | CA2260983A1 (fr) |
| CO (1) | CO4890841A1 (fr) |
| DE (1) | DE69721541T2 (fr) |
| DK (1) | DK0918761T3 (fr) |
| ES (1) | ES2197354T3 (fr) |
| HR (1) | HRP970412A2 (fr) |
| ID (1) | ID17453A (fr) |
| MA (1) | MA26435A1 (fr) |
| PA (1) | PA8434601A1 (fr) |
| PE (1) | PE1999A1 (fr) |
| PT (1) | PT918761E (fr) |
| TN (1) | TNSN97127A1 (fr) |
| WO (1) | WO1998003494A1 (fr) |
| ZA (1) | ZA976470B (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0918761B1 (fr) * | 1996-07-23 | 2003-05-02 | Neurogen Corporation | Derives benzylamine a substitution amido et amino, et classe de ligands specifiques du neuropeptide y1 |
| SE9703414D0 (sv) * | 1997-09-23 | 1997-09-23 | Astra Ab | New compounds |
| EP1033366A3 (fr) * | 1999-02-18 | 2000-12-27 | Pfizer Products Inc. | Dérivés d'amide comme antagonistes de récepteur de Neuropeptide Y (NPY) |
| CA2384041A1 (fr) * | 2000-07-05 | 2002-01-24 | Synaptic Pharmaceuticals Corporation | Antagonistes selectifs des recepteurs (mch1) d'hormone-1 de concentration de la melanine et utilisation de ceux-ci |
| US6569861B2 (en) | 2000-07-06 | 2003-05-27 | Neurogen Corporation | Melanin concentrating hormone receptor ligands |
| JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
| US7514438B2 (en) | 2003-08-13 | 2009-04-07 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
| WO2005049027A2 (fr) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinaisons utiles au traitement de troubles neuronaux |
| KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CN101891680B (zh) | 2004-06-24 | 2014-10-29 | 沃泰克斯药物股份有限公司 | Atp-结合弹夹转运蛋白的调控剂 |
| CN101374849A (zh) * | 2005-12-24 | 2009-02-25 | 沃泰克斯药物股份有限公司 | 作为abc转运蛋白调控剂的喹啉-4-酮衍生物 |
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| EP1834953A1 (fr) | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Dérivés de tetrahydropyrane comme Inhibiteurs de la 5- lipoxygénase |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| EP2481408A3 (fr) | 2007-03-01 | 2013-01-09 | Probiodrug AG | Nouvelle utilisation d'inhibiteurs glutaminyle cyclase |
| WO2008128985A1 (fr) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| KR101727762B1 (ko) | 2009-03-20 | 2017-04-17 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| WO2020172609A1 (fr) * | 2019-02-21 | 2020-08-27 | Marquette University | Ligands hétérocycliques de par1 et procédés d'utilisation |
| US11130743B2 (en) | 2019-02-21 | 2021-09-28 | Marquette University | Heterocyclic ligands of PAR1 and methods of use |
| CA3134613A1 (fr) | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Composes ciblant prmt5 |
| KR20220130127A (ko) * | 2019-12-19 | 2022-09-26 | 카스마 테라퓨틱스, 인코포레이티드 | Trpml 조절제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4845221A (en) * | 1988-04-15 | 1989-07-04 | American Home Products Corporation | Serotonergic substituted piperazinyl tetralins |
| IE950248L (en) * | 1989-04-22 | 1990-10-22 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5900415A (en) * | 1994-11-07 | 1999-05-04 | Pfizer Inc. | Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands |
| IL117997A0 (en) * | 1995-06-07 | 1996-10-31 | Pfizer | Neuropeptide Y1 specific ligands |
| EP0915859B1 (fr) * | 1996-07-23 | 2003-01-02 | Neurogen Corporation | Derives benzylamine substitues et nouvelle classe de ligands specifiques des neuropeptides y1 |
| US5985873A (en) * | 1996-07-23 | 1999-11-16 | Neurogen Corporation | Certain substituted benzylamine derivatives a new class of Neuropeptide-Y1 specific ligands |
| EP0918761B1 (fr) * | 1996-07-23 | 2003-05-02 | Neurogen Corporation | Derives benzylamine a substitution amido et amino, et classe de ligands specifiques du neuropeptide y1 |
-
1997
- 1997-07-18 EP EP97933564A patent/EP0918761B1/fr not_active Expired - Lifetime
- 1997-07-18 PT PT97933564T patent/PT918761E/pt unknown
- 1997-07-18 JP JP10507143A patent/JP2000515527A/ja not_active Ceased
- 1997-07-18 WO PCT/US1997/012690 patent/WO1998003494A1/fr not_active Ceased
- 1997-07-18 AU AU36718/97A patent/AU3671897A/en not_active Abandoned
- 1997-07-18 US US08/897,046 patent/US6133265A/en not_active Expired - Fee Related
- 1997-07-18 ES ES97933564T patent/ES2197354T3/es not_active Expired - Lifetime
- 1997-07-18 DE DE69721541T patent/DE69721541T2/de not_active Expired - Fee Related
- 1997-07-18 AT AT97933564T patent/ATE239002T1/de not_active IP Right Cessation
- 1997-07-18 CA CA002260983A patent/CA2260983A1/fr not_active Abandoned
- 1997-07-18 DK DK97933564T patent/DK0918761T3/da active
- 1997-07-21 TN TNTNSN97127A patent/TNSN97127A1/fr unknown
- 1997-07-22 ZA ZA976470A patent/ZA976470B/xx unknown
- 1997-07-22 MA MA24730A patent/MA26435A1/fr unknown
- 1997-07-22 PE PE1997000652A patent/PE1999A1/es not_active Application Discontinuation
- 1997-07-23 CO CO97041974A patent/CO4890841A1/es unknown
- 1997-07-23 HR HR60/022,298A patent/HRP970412A2/hr not_active Application Discontinuation
- 1997-07-23 AR ARP970103330A patent/AR008071A1/es unknown
- 1997-07-23 PA PA19978434601A patent/PA8434601A1/es unknown
- 1997-07-23 ID IDP972554A patent/ID17453A/id unknown
-
2000
- 2000-08-08 US US09/633,055 patent/US6316617B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0918761B1 (fr) | 2003-05-02 |
| DE69721541D1 (de) | 2003-06-05 |
| PA8434601A1 (es) | 2000-05-24 |
| PT918761E (pt) | 2003-09-30 |
| US6133265A (en) | 2000-10-17 |
| AR008071A1 (es) | 1999-12-09 |
| ID17453A (id) | 1998-01-08 |
| EP0918761A1 (fr) | 1999-06-02 |
| PE1999A1 (es) | 1999-02-02 |
| ES2197354T3 (es) | 2004-01-01 |
| CA2260983A1 (fr) | 1998-01-29 |
| DK0918761T3 (da) | 2003-08-25 |
| ZA976470B (en) | 1998-08-04 |
| US6316617B1 (en) | 2001-11-13 |
| JP2000515527A (ja) | 2000-11-21 |
| WO1998003494A1 (fr) | 1998-01-29 |
| TNSN97127A1 (fr) | 2005-03-15 |
| AU3671897A (en) | 1998-02-10 |
| CO4890841A1 (es) | 2000-02-28 |
| DE69721541T2 (de) | 2004-03-18 |
| ATE239002T1 (de) | 2003-05-15 |
| HRP970412A2 (en) | 1998-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26424A1 (fr) | Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26499A1 (fr) | Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant . | |
| FR2816938B1 (fr) | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant | |
| MA26479A1 (fr) | Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2735777B1 (fr) | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant | |
| MA26508A1 (fr) | Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation. | |
| MA26709A1 (fr) | Compositions pharmaceutiques de celecoxib, leurs procedes de preparation et methodes de traitement les utilisant | |
| MA26452A1 (fr) | Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2780057B1 (fr) | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
| FR2694290B1 (fr) | Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. | |
| FR2708608B1 (fr) | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. | |
| FR2665453B1 (fr) | Polylactides purifies, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26630A1 (fr) | 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| BG101715A (bg) | Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти | |
| MA26465A1 (fr) | Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26490A1 (fr) | Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant. | |
| DZ2866A1 (fr) | 1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| DZ2944A1 (fr) | Azalides nouveaux, procédé our leur préparation etcompositions pharmaceutiques les contenant. | |
| MA26791A1 (fr) | Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant. | |
| FR2716195B1 (fr) | Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant. | |
| DZ2155A1 (fr) | Aazétidines, procédé pour leur préparation, et co mpositions pharmaceutiques les contenant. | |
| ATE82681T1 (de) | 2',3'-dideoxy-3'-fluorothymidin und verwandte verbindungen zur behandlung von adenovirusinfektionen. |